Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Biree Andemariam is active.

Publication


Featured researches published by Biree Andemariam.


Biophysical Journal | 2003

A Two-Compartment Model of Osmotic Lysis in Plasmodium falciparum-Infected Erythrocytes

Marissa A. Wagner; Biree Andemariam; Sanjay A. Desai

We recently identified a voltage-dependent anion channel on the surface of human red blood cells (RBCs) infected with the malaria parasite, Plasmodium falciparum. This channel, the plasmodial erythrocyte surface anion channel (PESAC), likely accounts for the increased permeability of infected RBCs to various small solutes, as assessed quantitatively with radioisotope flux and patch-clamp studies. Whereas this increased permeability has also been studied by following osmotic lysis of infected cells in permeant solutes, these experiments have been limited to qualitative comparisons of lysis rates. To permit more quantitative examination of lysis rates, we have developed a mathematical model for osmotic fragility of infected cells based on diffusional uptake via PESAC and the two-compartment geometry of infected RBCs. This model, combined with a simple light scattering assay designed to track osmotic lysis precisely, produced permeability coefficients that match both previous isotope flux and patch-clamp estimates. Our model and light scattering assay also revealed Michaelian kinetics for inhibition of PESAC by furosemide, suggesting a 1:1 stoichiometry for their interaction.


British Journal of Haematology | 2010

Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura

Ellinor I.B. Peerschke; Biree Andemariam; Wei Yin; James B. Bussel

The role of the complement system in immune thrombocytopenic purpura (ITP) is not well defined. We examined plasma from 79 patients with ITP, 50 healthy volunteers, and 25 patients with non‐immune mediated thrombocytopenia, to investigate their complement activation/fixation capacity (CAC) on immobilized heterologous platelets. Enhanced CAC was found in 46 plasma samples (59%) from patients with ITP, but no samples from patients with non‐immune mediated thrombocytopenia. Plasma from healthy volunteers was used for comparison. In patients with ITP, an enhanced plasma CAC was associated with a decreased circulating absolute immature platelet fraction (A‐IPF) (<15 × 109/l) (P = 0·027) and thrombocytopenia (platelet count < 100 × 109/l) (P = 0·024). The positive predictive value of an enhanced CAC for a low A‐IPF was 93%, with a specificity of 77%. The specificity and positive predictive values increased to 100% when plasma CAC was defined strictly by enhanced C1q and/or C4d deposition on test platelets. Although no statistically significant correlation emerged between CAC and response to different pharmacological therapies, an enhanced response to splenectomy was noted (P < 0·063). Thus, complement fixation may contribute to the thrombocytopenia of ITP by enhancing clearance of opsonized platelets from the circulation, and/or directly damaging platelets and megakaryocytes.


Journal of Strain Analysis for Engineering Design | 2011

Microelasticity of red blood cells in sickle cell disease

Jamie L. Maciaszek; Biree Andemariam; George Lykotrafitis

Translation of cellular mechanics findings is crucial in many diseases, including Alzheimer’s disease, Parkinson’s disease, type II diabetes, malaria, sickle cell disease, and cancer. Atomic force microscopy (AFM) is appropriate for measuring mechanical properties of living and fixed cells due to its high force sensitivity and its ability to measure local and overall properties of individual cells under physiological conditions. A systemic force–displacement curve analysis is reported on the quantification of material stiffness via AFM using two theoretical models derived from the Hertz model. This analysis was applied to red blood cells from patients with sickle cell disease to determine the Young’s modulus of these cells in the oxygenated and deoxygenated state. Sickle cell disease pathophysiology is a consequence of the polymerization of sickle hemoglobin in red blood cells upon partial deoxygenation and the impaired flow of these cells in the microcirculation. A model is presented for a four-sided pyramidal indenter that is subsequently shown to have a better fit to the obtained data than that using a model of a parabolic indenter. It is concluded that deoxygenation and therapeutic treatment have a significant impact on the stiffness. This analysis presents a new approach to addressing medical disorders.


Pediatric Blood & Cancer | 2014

Identification of risk factors for an unsuccessful transition from pediatric to adult sickle cell disease care

Biree Andemariam; Jasmine Owarish‐Gross; James J. Grady; Donna Boruchov; Roger S. Thrall; J. Nathan Hagstrom

A successful transition from pediatric to adult sickle cell disease (SCD) care is paramount to continued improvements in survival. In order to enhance transition success, our pediatric SCD transition process was modified to include combined adult and pediatric provider clinics that incorporated participation by our local SCD community‐based organization. All children ages 16 and over participated in this newly‐formed transition program.


American Journal of Pathology | 2012

Splenic Morphological Changes Are Accompanied by Altered Baseline Immunity in a Mouse Model of Sickle-Cell Disease

Steven Szczepanek; Jeffrey T. McNamara; Eric R. Secor; Prabitha Natarajan; Linda Guernsey; Lauren A. Miller; Enrique Ballesteros; Evan R. Jellison; Roger S. Thrall; Biree Andemariam

Although functional asplenia from infarctions may be a major contributor to increased infectious mortality in sickle-cell disease (SCD), this relationship has not been fully defined. We used the transgenic Berkeley SCD mouse to define blood and splenic immunophenotypic differences in this model compared with C57BL/6 and hemizygous controls. In the serum of SCD mice, we found increased IgG2a and suppressed IgM, IgG2b, and IgA levels. Serum IL-6 levels in SCD mice were elevated, whereas IL-1α, CXCL10, and CCL5 levels were decreased. The blood of SCD mice had higher white blood cell counts, with an increased percentage of lymphocytes and decreases in other leukocytes. Immunophenotyping of lymphocytes revealed higher percentages of CD8(+) and T-regulatory cells and lower percentages of B cells. SCD mouse spleens exhibited histological disorganization, with reduction of defined lymphoid follicles and expansion of red pulp, a greater than fourfold increase in splenic mononuclear cells, marked expansion of the nucleated red blood cell fraction, and B-cell and CD8(+) T-cell lymphopenia. Within the splenic B-cell population, there was a significant decrease in B-1a B cells, with a corresponding decrease in IgA secreting plasma cells in the gut. Confocal microscopy of spleens demonstrated complete disruption of the normal lymphofollicular structure in the white pulp of SCD mice without distinct B, T, and marginal zones. Our findings suggest that altered SCD splenic morphological characteristics result in an impaired systemic immune response.


Leukemia & Lymphoma | 2012

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.

Rebecca Elstrom; Biree Andemariam; Peter Martin; Jia Ruan; Tsiporah Shore; Morton Coleman; John P. Leonard; Richard R. Furman

Abstract Patients with relapsed or refractory diffuse large B-cell lymphoma may experience extended survival with second-line chemotherapy and autologous stem cell transplant (ASCT). Since a major determinant of outcome after ASCT is responsiveness to second-line therapy, the development of more effective second-line treatments is desirable. We investigated the addition of bortezomib to rituximab, dexamethasone, ifosfamide, cisplatin and etoposide (VIPER). Fifteen patients were enrolled, of whom seven were refractory to first-line chemotherapy and only three had maintained first response for 1 year. Nine (60%) patients achieved objective responses, of which three (20%) were IWC-PET (International Workshop Criteria positron emission tomography) complete responses. Median progression-free survival was 3 months, and median overall survival was 10 months. At a median follow-up of 26 months, five patients (33%) remained alive. Treatment was well tolerated with no unexpected toxicity. Although response rates did not meet predefined criteria, activity was at least comparable to other second-line approaches despite a poor-prognosis patient population.


Biophysical Journal | 2012

Epinephrine Modulates BCAM/Lu and ICAM-4 Expression on the Sickle Cell Trait Red Blood Cell Membrane

Jamie L. Maciaszek; Biree Andemariam; Greg Huber; George Lykotrafitis

Collapse and sudden death in physical training are the most serious complications of sickle cell trait (SCT). There is evidence that erythrocytes in SCT patients aggregate during strenuous exercise, likely because of adhesive interactions with the extracellular matrix (ECM) and endothelial cells, and because of their irregular viscoelastic properties. This results in inflammation, blood flow impairment, and vaso-occlusive events. However, the exact role of stress conditions and how they lead to these complications is virtually unknown. Using single-molecule atomic force microscopy experiments, we found that epinephrine, a hormone that is secreted under stressful conditions, increases both the frequency and strength of adhesion events between basal cell adhesion molecule (BCAM/Lu) and ECM laminin, and between intercellular adhesion molecule-4 (ICAM-4) and endothelial α(v)β(3), compared with nonstimulated SCT erythrocytes. Increases in adhesion frequency provide significant evidence of the role of epinephrine in BCAM/Lu-laminin and ICAM-4-α(v)β(3) bonding, and suggest mechanisms of vaso-occlusion during physical exertion in SCT.


Journal of Biomechanics | 2014

Single-cell force spectroscopy as a technique to quantify human red blood cell adhesion to subendothelial laminin.

Jamie L. Maciaszek; Kostyantyn R. Partola; Jing Zhang; Biree Andemariam; George Lykotrafitis

Single-cell force spectroscopy (SCFS), an atomic force microscopy (AFM)-based assay, enables quantitative study of cell adhesion while maintaining the native state of surface receptors in physiological conditions. Human healthy and pathological red blood cells (RBCs) express a large number of surface proteins which mediate cell-cell interactions, or cell adhesion to the extracellular matrix. In particular, RBCs adhere with high affinity to subendothelial matrix laminin via the basal cell adhesion molecule and Lutheran protein (BCAM/Lu). Here, we established SCFS as an in vitro technique to study human RBC adhesion at baseline and following biochemical treatment. Using blood obtained from healthy human subjects, we recorded adhesion forces from single RBCs attached to AFM cantilevers as the cell was pulled-off of substrates coated with laminin protein. We found that an increase in the overall cell adhesion measured via SCFS is correlated with an increase in the resultant total force measured on 1 µm(2) areas of the RBC membrane. Further, we showed that SCFS can detect significant changes in the adhesive response of RBCs to modulation of the cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathway. Lastly, we identified variability in the RBC adhesion force to laminin amongst the human subjects, suggesting that RBCs maintain diverse levels of active BCAM/Lu adhesion receptors. By using single-cell measurements, we established a powerful new method for the quantitative measurement of single RBC adhesion with specific receptor-mediated binding.


Pediatric Research | 2013

Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccination.

Steven M. Szczepanek; Eric R. Secor; Sonali J. Bracken; Linda Guernsey; Ektor Rafti; Adam P. Matson; Roger S. Thrall; Biree Andemariam

Background:Children with sickle cell disease (SCD) are susceptible to recurrent infections, which are often life threatening and necessitate frequent vaccinations. Given the altered baseline immunity and proinflammatory state associated with SCD, we sought to determine the relative safety and efficacy of vaccination in transgenic SCD mice.Methods:Eight-week-old SCD mice were vaccinated with ovalbumin and aluminum hydroxide weekly for 3 wk by the intraperitoneal or intramuscular route. One week after the third vaccination, serum cytokines/chemokines, immunoglobulins, and bronchoalveolar lavage fluid cytokines were measured.Results:Only SCD mice were prone to mortality associated with vaccination, as 40% of the animals died after the intraperitoneal vaccinations and 50% died after the intramuscular vaccinations. Serum IgG2b and IgM were significantly lower in SCD mice than in C57BL/6 mice after vaccination, but ovalbumin-specific IgE was significantly higher. Serum interleukin (IL)-1α, IL-2, IL-5, macrophage inflammatory protein 1α, and granulocyte macrophage-colony stimulating factor were significantly lower in SCD mice than in C57BL/6 mice after vaccination, whereas bronchoalveolar lavage fluid IL-1β and IL-6 were increased.Conclusion:Mice with SCD appear to have a dysregulated immune response to vaccination. Thus, the relative safety and immunogenicity of vaccination should be studied in greater detail in the context of SCD.


Advanced Emergency Nursing Journal | 2010

Evidence-Based Sickle Cell Pain Management in the Emergency Department

Victoria Odesina; Sandra Bellini; Robin R. Leger; Robert Bona; Colleen Delaney; Biree Andemariam; Nancy Bacarro; Kathleen Lundquist; Sandra P. Donahoe; Susan DʼAngelo; Aleksandr Gorenbeyn; SueEllen Goodrich; Cheryl D. Tafas

This quality improvement project addressed the gaps in sickle cell pain management at a suburban teaching hospital emergency department. The aims were to (1) measure baseline pain management practices for patients with sickle cell disease in the ED and (2) implement an adapted emergency department sickle cell pain management clinical pathway. A retrospective chart review was conducted for data abstraction on pain management practices. Medical record review from 44 patient visits showed a high use of monotherapy, delay in time to medical evaluation, medication order, and time to first and subsequent analgesic administration and pain reassessments. Results were used by a multidisciplinary team to develop and implement an evidence-based clinical pathway to improve sickle cell disease pain management. The clinical pathway development was guided by both the advancing research through close collaboration model (ARCC) and Levines principles of conservation to provide holistic care while preserving vital organs.

Collaboration


Dive into the Biree Andemariam's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roger S. Thrall

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alexander J. Adami

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

Eric R. Secor

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar

James J. Grady

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

Linda Guernsey

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sasia Jones

University of Connecticut Health Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge